|
9. Basic and diluted loss per share
Summary of basic and diluted earnings per share
| |
|
Year ended December 31,
|
|
|
Year ended
December 31, |
|
|
|
Year ended
December 31, |
|
| |
|
2022 |
|
|
2021 |
|
|
|
2020 |
|
| |
|
£ |
|
|
£ |
|
|
|
£ |
|
| Loss for the year |
|
|
(1,389,706 |
) |
|
|
(13,575,925 |
) |
|
|
(5,457,916 |
) |
| Basic and diluted weighted average number of shares outstanding(1) |
|
|
687,199 |
|
|
|
390,585 |
|
|
|
378,481 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Basic and diluted loss per share |
|
|
(2.02 |
) |
|
|
(34.76 |
) |
|
|
(14.42 |
) |
| |
(1) |
On
November 18, 2022, TC BioPharm (Holdings) plc completed a reverse stock split of one (1) new share for every fifty (50) existing
shares effective November 21, 2022. As a result of the share split, all references in these financial statements and accompanying notes to units of ordinary shares or per share amounts are reflective of the reverse share
split for all periods presented. In addition, the exercise prices and the numbers of ordinary shares issuable upon the exercise of
any outstanding options to purchase ordinary shares were proportionally adjusted pursuant to the respective anti-dilution terms of
the share-based payment plans. |
Basic
loss per share is calculated by dividing the loss for the year attributable to the equity holders of the Company by the weighted average
number of shares outstanding during the year.
The
dilutive effect of potential shares through equity settled transactions were considered to be anti-dilutive as they would have decreased
the loss per share and were therefore excluded from the calculation of diluted loss per share.
|